# nova
D I S C O V E R Y

#insilico #insilicomedicine #clinicaltrialsimulation

# Simulating clinical trials
# with virtual patients

NOVA is a leading healthtech company which has developed a hybrid approach combining mechanistic models & artificial intelligence.

"A mere 10% improvement in predicting failures before a clinical trial could save $100 million in development costs per drug."
US Congress, 2017

US FDA selected NOVA for the Model-Informed Drug Development (MIDD) pilot program in 2019 to present its approach to model design and validation.

FDA **U.S. FOOD & DRUG** ADMINISTRATION

We help biotech and pharma companies generate in silico evidence to take informed decisions, drive down the potential clinical execution risk, accelerate research programs, and reduce cost of development.

We build computational models of disease and treatment based on knowledge extracted from scientific literature and real-world patient data.

Help answer new questions as the drug candidate progresses through the pipeline

**Discovery**
Streamline target identification & secure proof of concept

**Clinical Development**
Optimize trial design, select best biomarkers & capture best responders

**Market Access**
Demonstrate value to payers

JINKO is a unique in silico clinical trials simulation platform which offers an integrated suite of applications, from discovery to market access, to handle complex multi-scale models in a fully whitebox environment, to facilitate model auditing.

Mechanistic models of disease and virtual patients with JINKO are aimed at helping drug developers generate new insights and manage the complexity of human biology.

**Systemic knowledge review**
Knowledge Model

**02**

**Computational disease & drug models**
Computational Model

**?**

**Problem formulation**
Project plan

**01**

**03**

**04**

**06**

# jinkō
POWERED BY NOVA

**Virtual population**
Inter/intra-patient variability

**Simulation**
Research report

**05**

**Model validation**
Validation report and *in silico* study protocol

## Project portfolio

### STUDY PHASES

CLINICAL DEVELOPMENT
60%

DISCOVERY
20%

MARKET ACCESS
20%

### THERAPEUTIC AREAS

RESPIRATORY
14.3%

CARDIO
14.3%

ORPHAN
14.3%

ONCOLOGY
21.4%

METABOLIC
14.3%

INFECTIOUS
7.1%

IMMUNO
14.3%

## Our Clients

dbv technologies

eisbm
European Institute for Systems Biology & Medicine
A SYSTEMSSCOPE INSTITUTE

ElsaLys Biotech

ENYO PHARMA

erytech

innate pharma

janssen
PHARMACEUTICAL COMPANIES of Johnson-Johnson

ōm PHARMA

OP2 INNOVATIVE DRUGS

SERVIER

Shire

Takeda

THERA technologies

## Our Investors

SANOFI

Debiopharm